Switch theme
Sign up to access all valuation multiples
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
2014
24
LTM Revenue $17.0M
LTM EBITDA -$38.3M
$338M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Checkpoint Therapeutics has a last 12-month revenue (LTM) of $17.0M and a last 12-month EBITDA of -$38.3M.
In the most recent fiscal year, Checkpoint Therapeutics achieved revenue of $41K and an EBITDA of -$56.2M.
Checkpoint Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Checkpoint Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.0M | XXX | $41K | XXX | XXX | XXX |
| Gross Profit | $13.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$38.3M | XXX | -$56.2M | XXX | XXX | XXX |
| EBITDA Margin | -225% | XXX | -137010% | XXX | XXX | XXX |
| EBIT | -$35.9M | XXX | -$56.2M | XXX | XXX | XXX |
| EBIT Margin | -211% | XXX | -137010% | XXX | XXX | XXX |
| Net Profit | -$36.5M | XXX | -$56.2M | XXX | XXX | XXX |
| Net Margin | -214% | XXX | -137171% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Checkpoint Therapeutics's stock price is $4.
Checkpoint Therapeutics has current market cap of $371M, and EV of $338M.
See Checkpoint Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $338M | $371M | XXX | XXX | XXX | XXX | $-0.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Checkpoint Therapeutics has market cap of $371M and EV of $338M.
Checkpoint Therapeutics's trades at 8235.7x EV/Revenue multiple, and -6.0x EV/EBITDA.
Equity research analysts estimate Checkpoint Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Checkpoint Therapeutics has a P/E ratio of -10.1x.
See valuation multiples for Checkpoint Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $371M | XXX | $371M | XXX | XXX | XXX |
| EV (current) | $338M | XXX | $338M | XXX | XXX | XXX |
| EV/Revenue | 19.8x | XXX | 8235.7x | XXX | XXX | XXX |
| EV/EBITDA | -8.8x | XXX | -6.0x | XXX | XXX | XXX |
| EV/EBIT | -9.4x | XXX | -6.0x | XXX | XXX | XXX |
| EV/Gross Profit | 24.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.1x | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCheckpoint Therapeutics's last 12 month revenue growth is 493%
Checkpoint Therapeutics's revenue per employee in the last FY averaged $2K, while opex per employee averaged $2.3M for the same period.
Checkpoint Therapeutics's rule of 40 is -50137% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Checkpoint Therapeutics's rule of X is 1007% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Checkpoint Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 493% | XXX | 6630% | XXX | XXX | XXX |
| EBITDA Margin | -225% | XXX | -137010% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -50137% | XXX | -136517% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 1007% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 88176% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 137110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Checkpoint Therapeutics acquired XXX companies to date.
Last acquisition by Checkpoint Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Checkpoint Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Checkpoint Therapeutics founded? | Checkpoint Therapeutics was founded in 2014. |
| Where is Checkpoint Therapeutics headquartered? | Checkpoint Therapeutics is headquartered in United States of America. |
| How many employees does Checkpoint Therapeutics have? | As of today, Checkpoint Therapeutics has 24 employees. |
| Who is the CEO of Checkpoint Therapeutics? | Checkpoint Therapeutics's CEO is Mr. James F. Oliviero, III. |
| Is Checkpoint Therapeutics publicy listed? | Yes, Checkpoint Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Checkpoint Therapeutics? | Checkpoint Therapeutics trades under CKPT ticker. |
| When did Checkpoint Therapeutics go public? | Checkpoint Therapeutics went public in 2016. |
| Who are competitors of Checkpoint Therapeutics? | Similar companies to Checkpoint Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Checkpoint Therapeutics? | Checkpoint Therapeutics's current market cap is $371M |
| What is the current revenue of Checkpoint Therapeutics? | Checkpoint Therapeutics's last 12 months revenue is $17.0M. |
| What is the current revenue growth of Checkpoint Therapeutics? | Checkpoint Therapeutics revenue growth (NTM/LTM) is 493%. |
| What is the current EV/Revenue multiple of Checkpoint Therapeutics? | Current revenue multiple of Checkpoint Therapeutics is 19.8x. |
| Is Checkpoint Therapeutics profitable? | Yes, Checkpoint Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Checkpoint Therapeutics? | Checkpoint Therapeutics's last 12 months EBITDA is -$38.3M. |
| What is Checkpoint Therapeutics's EBITDA margin? | Checkpoint Therapeutics's last 12 months EBITDA margin is -225%. |
| What is the current EV/EBITDA multiple of Checkpoint Therapeutics? | Current EBITDA multiple of Checkpoint Therapeutics is -8.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
